RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
RegulatoryapprovedRasonquePositive
AI Analysis
Summary
The FDA approved Revolution Medicines' daraxonrasib (Rasonque) for pancreatic adenocarcinoma, with the decision coming 6.5 months earlier than the scheduled deadline.
Outcome Details
FDA approval granted 6.5 months ahead of deadline
Importance:9/10
Sentiment:
0.95
FDA approvalaccelerated timelinepancreatic cancerbreakthrough therapy
Related Companies
Read the original article
Published by BioSpace on August 26, 2026 3:28 PM